Literature DB >> 18073376

Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

Rune Kvåle1, Anssi Auvinen, Hans-Olov Adami, Asa Klint, Eivor Hernes, Bjørn Møller, Eero Pukkala, Hans H Storm, Laufey Tryggvadottir, Steinar Tretli, Rolf Wahlqvist, Elisabete Weiderpass, Freddie Bray.   

Abstract

Trends in incidence and mortality rates of prostate cancer were analyzed using data from the national cancer registries of Denmark, Finland, Iceland, Norway, and Sweden. Joinpoint regression models were used to quantify temporal trends for the period from 1980 to 2004. Incidence rates were increasing and similar in the Nordic countries during the 1980s. Around 1990, a more rapid incidence increase began in all Nordic countries except Denmark, where an increase was seen 5 years later. In 2001, incidence rates in Denmark were half of those seen in the other Nordic countries, but mortality rates varied only marginally among countries. Mean annual declines in prostate cancer mortality of 1.9% (95% CI = 0.4% to 3.3%) and 1.8% (95% CI = 0.5% to 3.0%) were observed from 1996 to 2004 in Finland and Norway, respectively. During the same period, mortality rates leveled off in Iceland and Sweden but continued to increase in Denmark. The rapid increase in incidence during the early 1990s coincided with the introduction of the prostate-specific antigen (PSA) test and conveys little information about the occurrence of potentially lethal disease. Mortality rates, however, have recently stabilized or declined in countries where PSA testing and curative treatment have been commonly practiced since the late 1980s. Although other explanatory factors may be in operation, these trends are consistent with a moderate effect of increased curative treatment of early diagnosed prostate cancer and improved treatment of more advanced disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073376     DOI: 10.1093/jnci/djm249

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  43 in total

1.  Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?

Authors:  Morten Valberg; Tom Grotmol; Steinar Tretli; Marit B Veierød; Tron A Moger; Susan S Devesa; Odd O Aalen
Journal:  Eur J Epidemiol       Date:  2016-07-18       Impact factor: 8.082

Review 2.  A critical review of the epidemiology of Agent Orange/TCDD and prostate cancer.

Authors:  Ellen T Chang; Paolo Boffetta; Hans-Olov Adami; Philip Cole; Jack S Mandel
Journal:  Eur J Epidemiol       Date:  2014-07-27       Impact factor: 8.082

3.  Early detection of prostate cancer: is screening in general practice justifiable?

Authors:  Emil L Sigurdsson
Journal:  Scand J Prim Health Care       Date:  2011-08-16       Impact factor: 2.581

4.  National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis.

Authors:  Subas Neupane; Freddie Bray; Anssi Auvinen
Journal:  World J Urol       Date:  2016-10-15       Impact factor: 4.226

5.  Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Authors:  Cindy Ke Zhou; David P Check; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Jacques Ferlay; Freddie Bray; Michael B Cook; Susan S Devesa
Journal:  Int J Cancer       Date:  2015-11-27       Impact factor: 7.396

6.  The heritability of prostate cancer in the Nordic Twin Study of Cancer.

Authors:  Jacob B Hjelmborg; Thomas Scheike; Klaus Holst; Axel Skytthe; Kathryn L Penney; Rebecca E Graff; Eero Pukkala; Kaare Christensen; Hans-Olov Adami; Niels V Holm; Elizabeth Nuttall; Steinbjorn Hansen; Mikael Hartman; Kamila Czene; Jennifer R Harris; Jaakko Kaprio; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-08       Impact factor: 4.254

7.  Prostate cancer incidence as an iceberg.

Authors:  Lorelei A Mucci; Claire H Pernar; Sam Peisch; Travis Gerke; Kathryn M Wilson
Journal:  Eur J Epidemiol       Date:  2017-05-30       Impact factor: 8.082

8.  PALB2 variants in hereditary and unselected Finnish prostate cancer cases.

Authors:  Sanna Pakkanen; Tiina Wahlfors; Sanna Siltanen; Mimmi Patrikainen; Mika P Matikainen; Teuvo L J Tammela; Johanna Schleutker
Journal:  J Negat Results Biomed       Date:  2009-12-15

9.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

10.  Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study.

Authors:  Katja Fall; Fang Fang; Lorelei A Mucci; Weimin Ye; Ove Andrén; Jan-Erik Johansson; Swen-Olof Andersson; Pär Sparén; Georg Klein; Meir Stampfer; Hans-Olov Adami; Unnur Valdimarsdóttir
Journal:  PLoS Med       Date:  2009-12-15       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.